Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Meropenem-Vaborbactam
Acute Pyelonephritis
Countdown
208days
Phase 2 readout · ~ Jan 31, 2027 estimated
What's at stake
Phase 2 trial results for Meropenem-Vaborbactam in Acute Pyelonephritis are due ~ Jan 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06672978: Phase 2 trial, sponsor Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), drug Meropenem-Vaborbactam. Primary completion date 2027-01 (estimated).”